Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.56 |
| ▸ | TNKS | O95271 | 6/20 | 0.56 |
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.56 |
| ▸ | WNT3A | P56704 | 4/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.56 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.56 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411302 | 1.00 | TNKS2 (0.56) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL20286634 | 0.90 | TNKS2 (0.46) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL25932351 | 0.82 | TNKS2 (0.40) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL15672303 | 0.82 | TNKS2 (0.40) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL16206263 | 0.78 | TNKS2 (0.55) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL21097251 | 0.75 | TNKS2 (0.68) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL7783488 | 0.72 | TNKS2 (1.00) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL13729610 | 0.71 | KIF11 (0.52) | KIF11CHUKTXNRD1NOX4ADORA3 | |
| SCHEMBL16010695 | 0.71 | KCNK3 (0.50) | ADORA3 | |
| SCHEMBL16179473 | 0.70 | PDE4B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220319704-A1 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | TESARO, INC. (US) | 2022-10-06 | — | — | US | claimed |
| US-12597519-B2 | Methods for characterizing and treating a cancer type using cancer images | TESARO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250387476-A1 | Methods of Treating Cancer | TESARO INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12415855-B2 | Methods of treating cancer with anti-PD-1 antibodies | TESARO, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240301057-A1 | METHODS OF TREATING CANCER WITH ANTI-TIM-3 ANTIBODIES | TESARO, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240158495-A1 | Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses Thereof | ANAPTYSBIO, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11926665-B2 | Methods of treating cancer with anti-TIM-3 antibodies | TESARO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230365928-A1 | CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365928-A1 | CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-11-16 | — | — | US | disclosed |
| US-20150301067-A1 | METHODS AND ASSAYS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150231266-A1 | Neurotherapeutic Nanoparticle Compositions and Devices | YALE UNIVERSITY | 2015-08-20 | — | — | US | disclosed |
| US-20150231266-A1 | Neurotherapeutic Nanoparticle Compositions and Devices | YALE UNIVERSITY | 2015-08-20 | — | — | US | disclosed |
| US-20150071930-A1 | COMBINATION THERAPY USING C-MET INHIBITOR AND BETA-CATENIN INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-03-12 | — | — | US | disclosed |
| US-20150071930-A1 | COMBINATION THERAPY USING C-MET INHIBITOR AND BETA-CATENIN INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-03-12 | — | — | US | disclosed |
| WO-2015016195-A1 | Wnt SIGNALING INHIBITOR | 協和発酵キリン株式会社 (JP) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014152321-A1 | ISOLATION OF NON-EMBRYONIC STEM CELLS AND USES THEREOF | THE JACKSON LABORATORY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140255426-A1 | WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130273649-A1 | Culture medium for pluripotent stem cells | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273649-A1 | Culture medium for pluripotent stem cells | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK2, CHEK1 | TNKS2 18/4885TNKS 15/4885PARP1 5/4885 |
| US-20150071930-A1 | COMBINATION THERAPY USING C-MET INHIBITOR AND BETA-CATENIN INHIBITOR | CTNNB1, MET, CTNNA1 | TNKS2 1536/4885TNKS 1240/4885PARP1 1765/4885 |
| US-20240158495-A1 | Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses Thereof | CD2, CD58, CD4 | TNKS2 2695/4885TNKS 3128/4885PARP1 1942/4885 |
| US-20150231266-A1 | Neurotherapeutic Nanoparticle Compositions and Devices | BDNF, LIFR, NTRK2 | TNKS2 2941/4885TNKS 2192/4885PARP1 4744/4885 |
| US-20250387476-A1 | Methods of Treating Cancer | PDCD1LG2, PDCD1, CD274 | TNKS2 608/4885TNKS 580/4885PARP1 19/4885 |
| US-11926665-B2 | Methods of treating cancer with anti-TIM-3 antibodies | HAVCR2, LGALS3BP, LGALS3 | TNKS2 1104/4885TNKS 1202/4885PARP1 440/4885 |
| US-12415855-B2 | Methods of treating cancer with anti-PD-1 antibodies | CD274, PDCD1LG2, PDCD1 | TNKS2 1270/4885TNKS 748/4885PARP1 101/4885 |
| US-20240301057-A1 | METHODS OF TREATING CANCER WITH ANTI-TIM-3 ANTIBODIES | HAVCR2, LGALS3BP, LGALS3 | TNKS2 1104/4885TNKS 1202/4885PARP1 440/4885 |
| US-12597519-B2 | Methods for characterizing and treating a cancer type using cancer images | BRCA1, RAD51, RAD54L | TNKS2 418/4885TNKS 325/4885PARP1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.